Skip to main content
SpringerLink
Log in

Bevacizumab/protein tyrosine kinase inhibitors

Various toxicites in paediatric patients: 15 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. De Pasquale MD, Castellano A, De Sio L, De Laurentis C, Mastronuzzi A, Serra A, Cozza R, Jenkner A, De Ioris MA.Bevacizumab in pediatric patients: How safe is it?. Anticancer Research 31: 3953-3957, No. 11, Nov 2011 - Italy

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bevacizumab/protein tyrosine kinase inhibitors. React. Wkly. 1389, 13 (2012). https://doi.org/10.2165/00128415-201213890-00038

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201213890-00038

Keywords

Search

Navigation